Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | CA1 | P00915 | 4/20 | 0.44 |
| ▸ | CA2 | P00918 | 4/20 | 0.44 |
| ▸ | CA12 | O43570 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 2/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7448758 | 0.87 | KMT2A (0.39) | MAPTCA12CA14ALDH1A1RAB9A | |
| SCHEMBL3622209 | 0.85 | CA1 (0.52) | MAPTCA1CA2CA12CA9 | |
| SCHEMBL506934 | 0.84 | ANPEP (0.45) | MAPTCA1CA2TDP1TSHR | |
| SCHEMBL15441561 | 0.84 | CA1 (0.47) | MAPTCA1CA2CA12CA9 | |
| SCHEMBL26262430 | 0.81 | CA1 (0.44) | MAPTCA1CA2CA12CA9 | |
| SCHEMBL2874909 | 0.81 | CPT1B (0.39) | MAPTCA1CA2CA12CA9 | |
| SCHEMBL5414405 | 0.80 | MIF (0.40) | MAPTTDP1 | |
| SCHEMBL9995953 | 0.80 | MIF (0.40) | MAPTTDP1 | |
| SCHEMBL2357009 | 0.80 | LMNA (0.37) | MAPTTSHRALDH1A1RAB9ANPC1 | |
| SCHEMBL1039225 | 0.80 | ALOX5 (0.39) | TDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103003234-B | N-hydroxyformamide derivative and pharmaceutical containing same | KAKEN PHARMACEUTICAL CO.,LTD. (JP) | 2014-10-22 | — | — | CN | disclosed |
| CN-103189501-A | Composition for maintaining platelet function | UNIV TOKYO | 2013-07-03 | — | — | CN | disclosed |
| CN-103003234-A | N-hydroxyformamide derivative and pharmaceutical containing same | KAKEN PHARMA CO LTD | 2013-03-27 | — | — | CN | disclosed |
| EP-1758883-B1 | Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors | SCHERING CORP (US) | 2011-11-02 | — | — | EP | disclosed |
| US-7511062-B2 | Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors | SCHERING CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| EP-1758883-A1 | SUBSTITUTED 2-QUINOLYL-OXAZOLES USEFUL AS PDE4 INHIBITORS | SCHERING CORPORATION (US) | 2007-03-07 | — | — | EP | disclosed |
| US-20060106062-A1 | Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors | SCHERING CORPORATION | 2006-05-18 | — | — | US | disclosed |
| WO-2005116009-A1 | SUBSTITUTED 2-QUINOLYL-OXAZOLES USEFUL AS PDE4 INHIBITORS | SCHERING CORPORATION (US) | 2005-12-08 | — | — | WO | disclosed |
| CN-1067988-C | Indoloylguanidine derivatives | SUMITOMO PHARMACEUTICS K K (JP) | 2001-07-04 | — | — | CN | disclosed |
| CN-1136038-A | Indoloylguanidine derivatives | SUMITOMO PHARMACEUTICS K K (JP) | 1996-11-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106062-A1 | Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors | PDE4A, PDE4B, PDE3B | MAPT 4872/4885CA1 2626/4885CA2 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.